Immunocellular Therapeutics
1987
FOUNDED
PUBLIC
STATUS
1-10
EMPLOYEES
IMUC
STOCK SYMBOL
$0.05
SHARE PRICE
(As of Friday Closing)
Description
ImmunoCellular Therapeutics Ltd is a US-based clinical-stage biotechnology company. It is engaged in developing immune-based therapies for the treatment of cancers which can elicit an immune response against several antigens. The company has developed ICT-107, which is a dendritic cell (DC) immunotherapy for the treatment of newly diagnosed glioblastoma multiforme (GBM), which is a lethal type of brain cancer. It develops Immunotherapies for treating cancer in which a patient's own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies.
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
PINX
Primary Office
- 23622 Calabasas Road
- Suite 300
- Calabasas, CA 91302
- United States
+1 (818) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Immunocellular Therapeutics’s full profile, request a free trial.
Immunocellular Therapeutics Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $0.01 - $0.05 | $1.82M | $0.04 | 134K |
Immunocellular Therapeutics Financials Summary
|
In Thousands,
USD |
TTM
30-Jun-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
FY 2015
31-Dec-2015
|
|---|---|---|---|---|
| Enterprise Value | 5,871 | 5,116 | (5,895) | 7,652 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (5,650) | (13,386) | (20,723) | (12,641) |
| Net Income | (5,664) | (14,312) | (22,086) | (12,791) |
| Total Assets | 3,829 | 7,009 | 16,890 | 30,082 |
| Total Debt | 574 | 1,959 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Immunocellular Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Immunocellular Therapeutics‘s full profile, request access.
Request full access to PitchBookImmunocellular Therapeutics Competitors (36)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Celgene | Pending Transaction (M&A) | Summit, NJ | 0000 | 000.00 | 000000&0 | 000.00 |
| 0000 000000 | Formerly VC-backed | Santa Monica, CA | 000 | 00000 | 000000&0 | 00000 |
| 0000000000 0000000 | Venture Capital-Backed | Mont-Saint-Guibert, Belgium | 00 | 00000 | 00000000000 | 00000 |
| 000000000 | Private Equity-Backed | Gaithersburg, MD | 000.00 | 0000000 0000 | 000.00 | |
| 000000 00000000000 | Venture Capital-Backed | San Diego, CA | 000.00 | 00000000000 | 000.00 |
Immunocellular Therapeutics Executive Team (6)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Gary Titus | Chairman & Board Member |
5 Former Executives
You’re viewing 1 of 6 executives. Get the full list »Immunocellular Therapeutics Board Members (17)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| 0000 00000 | Immunocellular Therapeutics | Chairman & Board Member | 000 0000 | |
| 0000 00 00 | Immunocellular Therapeutics | Board Member | 000 0000 | |
| 00000 0000000 00.0 | Self | Board Member | 000 0000 |
14 Former Board Members
You’re viewing 3 of 17 board members. Get the full list »